[HTML][HTML] Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies

ER Elliot, A Theodoraki, LR Jain, NJ Marshall… - Clinical …, 2016 - ncbi.nlm.nih.gov
Ritonavir and cobicistat, used as pharmacokinetic enhancers in combination with some
antiretrovirals (ARVs) for the treatment of HIV, are potent inhibitors of the CYP3A4 isoenzyme. …

Thyrotoxicosis associated with the use of amiodarone: the utility of ultrasound in patient management

A Theodoraki, MPJ Vanderpump - Clinical endocrinology, 2016 - Wiley Online Library
Amiodarone is an anti‐arrhythmic drug that commonly affects the thyroid, causing hypothyroidism
or thyrotoxicosis. Amiodarone‐induced thyrotoxicosis ( AIT ) is caused by excessive …

Cell‐type‐specific modulation of innate immune signalling by vitamin D in human mononuclear phagocytes

R Kundu, A Theodoraki, CT Haas, Y Zhang… - …, 2017 - Wiley Online Library
Vitamin D is widely reported to inhibit innate immune signalling and dendritic cell ( DC )
maturation as a potential immunoregulatory mechanism. It is not known whether vitamin D has …

Distinct patterns of heparan sulphate in pancreatic islets suggest novel roles in paracrine islet regulation

A Theodoraki, Y Hu, S Poopalasundaram… - Molecular and cellular …, 2015 - Elsevier
Heparan sulphate proteoglycans (HSPGs) exist in pancreatic beta cells, and HS seems to
modulate important interactions in the islet microenvironment. However, the intra-islet …

Testosterone therapy in men

A Theodoraki, PM Bouloux - Menopause International, 2009 - journals.sagepub.com
Androgens exert effects on virtually all bodily tissues, and have a multitude of physiological
roles in health. Testosterone, the predominant androgen in men, when deficient (…

[HTML][HTML] Radiology reporting of adrenal incidentalomas–who requires further testing?

F Paterson, A Theodoraki, A Amajuoyi… - Clinical …, 2014 - ncbi.nlm.nih.gov
Adrenal incidentalomas (AIs) are common and guidelines recommend testing to exclude
functioning lesions and malignancy. Their increasing prevalence results in several …

Malignant somatostatinoma presenting with diabetic ketoacidosis and inhibitory syndrome: pathophysiologic considerations

A Theodoraki, B Khoo, A Hamda, F Grillo, T Meyer… - Endocrine Practice, 2010 - Elsevier
Objective To describe a patient with diabetic ketoacidosis secondary to a malignant
somatostatinoma. Methods We present the clinical, laboratory, radiologic, and pathologic findings of …

[HTML][HTML] PCSK9 inhibitors and treatment targets: an audit-based evaluation of a specialist lipid clinic

A Suresh, A Theodoraki, E Ward… - British Journal of Diabetes, 2022 - bjd-abcd.com
Background: Trial evidence for lower LDL cholesterol (LDL-C) treatment targets for
cardiovascular benefit were incorporated into recent European Society of Cardiology/European …

Running on empty

D Wild, A Theodoraki, TR Kurzawinski… - European journal of …, 2010 - Springer
A patient presented with spells of light-headedness, confusion and collapses, improving on
eating. During a supervised fast, plasma glucose dropped to 1.7 mmol/l, with inappropriately …

[PDF][PDF] PCSK9 inhibitor therapy: delayed-onset cutaneous reactions

S Bukhari, A Theodoraki, E Ward, E Nogueira… - British Journal of …, 2023 - bjd-abcd.com
Cutaneous side-effects have been associated following initiation of PCSK9 inhibitors. 1, 2
We report two cases where there was a delayed onset of cutaneous side-effects.